glp3.wiki
Regulatory status

Editorially reviewed · Last updated September 8, 2026 · How we review

Orforglipron vs Rybelsus (Oral Semaglutide): Two Oral GLP-1 Pills Compared

Part of Weight Loss Drug Comparison Index.

Orforglipron vs Rybelsus (Oral Semaglutide): Two Oral GLP-1 Pills Compared

Orforglipron is now approved as Foundayo for adult weight management; Rybelsus is an oral semaglutide medicine with diabetes-related indications. Both are daily GLP-1 pills, but they are not interchangeable treatments. Rybelsus requires a morning fasting routine; Foundayo can be taken with or without food. Foundayo label, Rybelsus label

In ACHIEVE-3, orforglipron outperformed the tested oral semaglutide doses on blood sugar and weight in adults with type 2 diabetes. That is a direct trial result, but it does not make Foundayo an approved diabetes replacement or establish superiority over oral Wegovy.

Reviewed September 8, 2026. This comparison separates the current US labels from historical research doses.

Side-by-Side Comparison

Foundayo (orforglipron)Rybelsus (oral semaglutide)
DeveloperEli LillyNovo Nordisk
MoleculeNon-peptide small moleculePeptide formulated with SNAC
Receptor and routeGLP-1; daily pillGLP-1; daily pill
US approved usesAdult weight reduction and long-term maintenanceAdult type 2 diabetes; cardiovascular risk reduction in eligible adults with type 2 diabetes
Food and water routineWith or without foodEmpty stomach in the morning; up to 4 oz water; wait at least 30 minutes
Marketed tablet strengths0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg3, 7 and 14 mg
Diabetes head-to-head evidenceACHIEVE-3 tested an investigational formulationACHIEVE-3 tested 7 mg and 14 mg oral semaglutide
Approved weight-management use requires obesity, or overweight with a weight-related condition, alongside diet and activity. Rybelsus’s cardiovascular indication is for adults with type 2 diabetes at high risk of major cardiovascular events. Neither indication should be inferred from weight loss alone. Sources: Foundayo prescribing information and Rybelsus prescribing information.

How the Mechanisms Differ

Orforglipron: Small Molecule, No Fasting Requirement

Orforglipron activates the GLP-1 receptor and reduces calorie intake through effects on appetite. Its non-peptide formulation allows oral dosing without the fasting routine required by semaglutide tablets. This is a practical difference, not proof of greater safety. Foundayo label, sections 2 and 12

Laboratory descriptions such as “partial agonist” or “biased agonism” do not establish a clinical weight-loss ceiling or predict which medicine an individual will tolerate. The head-to-head trial is more useful than an assumed ranking based on chemistry.

Rybelsus: Peptide Needing Protection

Rybelsus contains semaglutide, also used in other Novo Nordisk products, with salcaprozate sodium (SNAC) to facilitate absorption. Absorption occurs predominantly in the stomach. The label estimates Rybelsus bioavailability at 0.4% to 1%. That describes how much reaches the circulation; it does not mean the rest was necessarily destroyed by stomach acid. Rybelsus label, section 12.3
The current label also covers Ozempic tablets, supplied in 1.5, 4 and 9 mg strengths. Rybelsus and Ozempic tablets have different formulations and are not substitutable milligram for milligram. Oral Wegovy is another distinct product. Check the exact brand and strength on the prescription rather than treating every semaglutide tablet as Rybelsus.

Weight Loss Comparison

Head-to-Head: ACHIEVE-3 Trial

ACHIEVE-3 was a 52-week, randomized, open-label Phase 3 trial in 1,698 adults whose type 2 diabetes was inadequately controlled with metformin. It compared orforglipron 12 mg and 36 mg with oral semaglutide 7 mg and 14 mg. These orforglipron doses refer to the investigational formulation, not current Foundayo tablet strengths. Lilly’s detailed ACHIEVE-3 results
Week 52 outcomeOral semaglutide 14 mgOrforglipron 36 mg (trial formulation)
HbA1c change, efficacy estimand−1.4 percentage points−2.2 percentage points
Weight change, efficacy estimand−5.3%−9.2%
HbA1c below 7%, efficacy estimand66.1%85.4%
HbA1c change, treatment-regimen estimand−1.5 percentage points−1.9 percentage points
Weight change, treatment-regimen estimand−5.3%−8.2%
The efficacy analysis estimates outcomes if participants remained on treatment without additional glucose-lowering therapy. The treatment-regimen analysis includes the effects of discontinuation and additional treatment. Both favored orforglipron at these doses. Neither compared it with Wegovy 25 mg tablets, and neither established which drug is best for a person without diabetes.

Obesity-Specific Trial Data

Swipe sideways to see every column.

Study and populationDose described by sourceTimepointMean weight change
ATTAIN-1; adults without diabetesOrforglipron 36 mg trial formulation72 weeks−12.4% efficacy estimand; −11.2% treatment-regimen estimand
OASIS 1; adults without diabetesOral semaglutide 50 mg research dose68 weeks−15.1% treatment-policy estimand
OASIS 4 / Wegovy label Study 7; adults without diabetesOral semaglutide 25 mg64 weeks−13.6% intention-to-treat analysis in the label
Sources: ATTAIN-1 full results, OASIS 1 abstract, OASIS 4 publication and Wegovy label, Study 7.
These separate trials are context, not a head-to-head ranking. The current Foundayo label reports 11.1% average loss at the equivalent marketed 17.2 mg dose in its intention-to-treat analysis of ATTAIN-1. That is a different reported analysis from the publication’s 12.4% efficacy estimate. Rybelsus is not approved for obesity, and 50 mg is not the marketed oral Wegovy maintenance dose.

Weight Loss Thresholds (ATTAIN-1)

In Lilly’s published ATTAIN-1 efficacy analysis, 59.6% of participants assigned the highest research dose lost at least 10% of their weight, and 39.6% lost at least 15%. These are obesity-trial results, not Rybelsus head-to-head results. The lower treatment-regimen figures were 54.6% and 36.0%, respectively. ATTAIN-1 results table

Side Effects Comparison

Both medicines can cause gastrointestinal symptoms. The useful direct comparison here is ACHIEVE-3, rather than juxtaposing unrelated obesity and diabetes trials. Treatment stopped because of adverse events in 9.7% of the orforglipron 36 mg group and 4.9% of the oral semaglutide 14 mg group. This does not prove that every symptom was more common with orforglipron or that Rybelsus is safer for every patient. ACHIEVE-3 safety results
Both labels warn about pancreatitis, severe gastrointestinal reactions, dehydration-related kidney injury and gallbladder disease. Both have a boxed thyroid C-cell tumor warning and contraindications for a personal or family history of medullary thyroid carcinoma or MEN 2. A pill is not automatically a low-risk version of a GLP-1 injection. Foundayo label, Rybelsus label
Foundayo also has specific CYP3A4 and simvastatin interactions. A pharmacist should review the complete medicine list before treatment or a switch. The absence of a fasting requirement does not mean it can be combined freely with other medicines.

Dosing Convenience: The Core Differentiator

Rybelsus Dosing Restrictions

The label says to:

  1. Take it on an empty stomach in the morning.
  2. Swallow the tablet whole with up to 4 oz of plain water.
  3. Wait at least 30 minutes before food, other drinks or other oral medicines.
  4. Do not split, crush, chew or dissolve the tablet.
These requirements support absorption. Ask a pharmacist how to arrange other morning medicines rather than changing their timing yourself. Rybelsus administration instructions

Orforglipron: No Fasting Requirement

Foundayo is taken once daily, with or without food, and swallowed whole. It has no Rybelsus-style fasting or water-volume restriction. However, it still needs gradual escalation and an interaction review. Its label advises extra contraceptive precautions for people using oral hormonal contraception after starting treatment and after dose increases. Foundayo label, sections 2, 7 and 8

Cost and Availability

Rybelsus (Available Now)

Rybelsus is approved for adult type 2 diabetes and cardiovascular risk reduction in eligible adults with type 2 diabetes; it is not approved for weight management. When comparing costs, ask your plan about the exact product and indication rather than assuming a diabetes medicine will have the same coverage as an obesity medicine. Current Rybelsus label

Orforglipron (Available as Foundayo)

Foundayo is available by prescription. Lilly’s US self-pay programs advertise prices starting at $149 for a 30-day supply, with dose-specific prices and eligibility conditions. This is an offer price, not a guarantee of an individual’s cost. Check the current Foundayo coverage and savings terms.

A lower manufacturing cost does not establish a lower pharmacy bill. Compare what you would pay at the prescribed maintenance dose, including the conditions for refills, instead of relying on projected prices from before approval.

Oral Semaglutide at Higher Doses: The Wegovy Pill

The names and strengths are easy to confuse:

  • Rybelsus: 3, 7 and 14 mg semaglutide tablets with diabetes-related indications.
  • Ozempic tablets: a different semaglutide formulation in 1.5, 4 and 9 mg strengths; not substitutable with Rybelsus milligram for milligram.
  • Wegovy tablets: 1.5, 4 and 9 mg escalation strengths followed by a 25 mg daily maintenance dose for its adult labeled uses.
  • Oral semaglutide 50 mg: the dose studied in OASIS 1, not a marketed Wegovy tablet strength in the current US label.
Sources: Rybelsus/Ozempic tablet label, Wegovy label and OASIS 1.

For a weight-management decision, Foundayo and oral Wegovy have a closer overlap in approved purpose than Foundayo and Rybelsus. ACHIEVE-3 does not answer that comparison.

Where Retatrutide Fits

Retatrutide is an investigational weekly injection targeting GIP, GLP-1 and glucagon receptors. It is not an oral alternative or an approved replacement for either pill. Its separate trial results cannot establish superiority over the medicines in this comparison. Lilly’s retatrutide overview
See Retatrutide vs Orforglipron and Oral vs Injectable GLP-1 Drugs for that context.

Frequently Asked Questions

Is orforglipron better than Rybelsus for weight loss?

In ACHIEVE-3, the highest orforglipron research dose produced greater average weight loss than oral semaglutide 14 mg in adults with type 2 diabetes: 9.2% versus 5.3% using the efficacy analysis at 52 weeks. That does not compare Foundayo with oral Wegovy or make Foundayo an approved replacement for diabetes treatment.

Does orforglipron have to be taken on an empty stomach?

No. Foundayo can be taken with or without food. It still has medicine interactions and dose-escalation instructions, so “no fasting requirement” does not mean “no restrictions.”

Why does Rybelsus need to be taken on an empty stomach?

The tablet uses SNAC to help semaglutide absorb through the stomach. The label’s morning fasting, water and waiting instructions support that absorption. Follow the instructions for the exact semaglutide product you were prescribed.

Can I switch from Rybelsus to orforglipron?

Ask the prescriber what each medicine is treating. Foundayo’s current approval is for adult weight management; Rybelsus has diabetes and cardiovascular indications. There is no milligram-for-milligram conversion, and the Foundayo label does not recommend combining it with another GLP-1 receptor agonist. Do not stop a working diabetes treatment simply because another medicine is a more convenient pill.

When will orforglipron be available?

It is already available in the US as prescription Foundayo for eligible adults needing weight management. The former forecast of an FDA decision in Q2 2026 is outdated.

What are the side effects of orforglipron compared to Rybelsus?

Both can cause gastrointestinal symptoms and have important warnings. ACHIEVE-3 reported more adverse-event discontinuations with the highest orforglipron research dose than with oral semaglutide 14 mg. This is a trial-specific finding, not proof that one drug is safer for every person.

Is Rybelsus approved for weight loss?

No. Rybelsus has adult type 2 diabetes and cardiovascular risk-reduction indications. Oral Wegovy is the semaglutide tablet with a weight-management indication, with a 25 mg daily maintenance dose after escalation.

Sources

  1. Eli Lilly. Foundayo prescribing information.
  2. Novo Nordisk. Rybelsus and Ozempic tablets prescribing information.
  3. Eli Lilly. Detailed ACHIEVE-3 results, published in The Lancet. February 26, 2026.
  4. Eli Lilly. ATTAIN-1 full results. September 16, 2025.
  5. Knop FK, et al. OASIS 1: oral semaglutide 50 mg. The Lancet, 2023.
  6. Wharton S, et al. OASIS 4: oral semaglutide 25 mg. New England Journal of Medicine, 2025.
  7. Novo Nordisk. Wegovy prescribing information.
  8. Eli Lilly. Foundayo coverage and savings.
This article is for information, not a prescription or switching plan. Foundayo and Rybelsus are FDA-approved for different uses; retatrutide remains investigational. Discuss your condition, other medicines and treatment goals with your clinician. This site is not affiliated with Eli Lilly, Novo Nordisk or any pharmaceutical manufacturer.
How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Foundayo is FDA-approved for adult weight management. Rybelsus is approved for adult type 2 diabetes and cardiovascular risk reduction in eligible adults with type 2 diabetes. Retatrutide remains investigational.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all compare topics →